The goal is to fine-tunethe diagnostic assignment of breast cancer cases with the hope that this willadequately address and improve the effectiveness of selecting treatmentmodalities, particularly in regard to the choice of use of monoclonalantibodies (MoAbs) and small moleculetyrosine kinase inhibitors (smTKIs) against EGFR, a clinical strategy collectively referred to as anti-EGFRtherapy. This evidence concerns the gene EGFR and breast cancer.